The Vitiligo Therapeutics Market is Expected to Show Moderate Growth up to 2019
GlobalData estimated the global vitiligo therapeutics market to be worth $1.4 billion in 2011. It is expected to grow to $2.7 billion by 2019 at a Compound Annual Growth Rate (CAGR) of 8.8%. This growth can be primarily attributed to the rise in the number of patients undergoing treatment for vitiligo and the launch of Scenesse (afamelanotide) in 2014. The vitiligo therapeutics market will witness only one new drug approval in the forecast period. The new introduction in the market will be positioned as a novel therapy among moderately efficacious generics and is expected to be launched at a premium price, thus limiting its market penetration in initial years. The market will be characterized with the dominance of generic products as only one new product is scheduled to be launched in the forecast period.
The prominence of generics in the market and the new drug introduction will lead to steady growth in the vitiligo therapeutics market over the forecast period. The market is expected to witness moderate growth with generics playing a major role in the forecast period, which is similar to the present market scenario.
Generics will Continue to Dominate the Vitiligo Therapeutics Market in the Forecast Period
GlobalData found that the treatment options currently available in the vitiligo therapeutics market are generics. Only Scenesse from Clinuvel Pharmaceuticals is expected to be launched in the forecast period. The vitiligo therapeutics pipeline is deprived of drug candidates in the late stage of clinical development.
Current Competition in the Vitiligo Therapeutics Market is Weak
GlobalData assessed the current competitive landscape for vitiligo drugs and found that competition is weak. All the available treatment options are moderately successful in meeting the market demand. Although the market has various treatment options available, none are able to manage vitiligo adequately. The products currently available in the market are associated with average efficacy and safety profiles. While current treatment options are capable of inducing some degree of repigmentation in the affected areas, they lack in ceasing disease progression and to impart satisfactory levels of repigmentation.
As the products currently in the market do not serve the unmet need, the market continues to offer opportunities for products in the pipeline with novel mechanism of action and disease modifying characteristics. The unmet need in the vitiligo therapeutics market is considered to be significant and can be fulfilled by technologically advanced products with improved safety and efficacy profiles.
Weak Pipeline Lacking in Effective Therapeutic Options in Late Phase of Clinical Development
GlobalData’s research indicates that the vitiligo therapeutics market pipeline is weak as the pipeline has few therapeutic treatment options. There are seven potential treatment options in the pipeline across various phases of clinical development. Out of the seven pipeline candidates, three are melanocytes transplantation therapies and the remaining four are therapeutic treatments. None of the therapeutic treatment options in the pipeline is in the late stage of development. In Phase III there are three melanocytes transplantation therapies, which will improve the disease management through surgical treatment options. In terms of therapeutic treatment options all of the molecules in the pipeline are first-in-class. The only first-in-class molecule in Phase II, Scenesse (afamelanotide) from Clinuvel Pharmaceuticals, acts by stimulating alpha-melanocytes. Of the three first-in-class molecules from the preclinical phase, DRM02 of Dermira, is a topical kinase inhibitor whereas two molecules from Switch Biotech, SWT05104 and SWT05105 are melanocytes formation stimulators. Scenesse is an analogue of alpha melanocytes stimulating hormone and mimics its action. Treatment of vitiligo patients with Scenesse is expected to facilitate repigmentation by enhancing the growth of melanocytes, assisting in their migration to depigmented areas of skin and activating pigment production within these regions.
GlobalData estimated the global vitiligo therapeutics market to be worth $1.4 billion in 2011. It is expected to grow to $2.7 billion by 2019 at a Compound Annual Growth Rate (CAGR) of 8.8%. This growth can be primarily attributed to the rise in the number of patients undergoing treatment for vitiligo and the launch of Scenesse (afamelanotide) in 2014. The vitiligo therapeutics market will witness only one new drug approval in the forecast period. The new introduction in the market will be positioned as a novel therapy among moderately efficacious generics and is expected to be launched at a premium price, thus limiting its market penetration in initial years. The market will be characterized with the dominance of generic products as only one new product is scheduled to be launched in the forecast period.
The prominence of generics in the market and the new drug introduction will lead to steady growth in the vitiligo therapeutics market over the forecast period. The market is expected to witness moderate growth with generics playing a major role in the forecast period, which is similar to the present market scenario.
Generics will Continue to Dominate the Vitiligo Therapeutics Market in the Forecast Period
GlobalData found that the treatment options currently available in the vitiligo therapeutics market are generics. Only Scenesse from Clinuvel Pharmaceuticals is expected to be launched in the forecast period. The vitiligo therapeutics pipeline is deprived of drug candidates in the late stage of clinical development.
Vitiligo Therapeutics Market
Published: February 2012
No. of Pages: 63
: Single User License - US$3995 Corporate User License - US$11985
No. of Pages: 63
: Single User License - US$3995 Corporate User License - US$11985
GlobalData assessed the current competitive landscape for vitiligo drugs and found that competition is weak. All the available treatment options are moderately successful in meeting the market demand. Although the market has various treatment options available, none are able to manage vitiligo adequately. The products currently available in the market are associated with average efficacy and safety profiles. While current treatment options are capable of inducing some degree of repigmentation in the affected areas, they lack in ceasing disease progression and to impart satisfactory levels of repigmentation.
As the products currently in the market do not serve the unmet need, the market continues to offer opportunities for products in the pipeline with novel mechanism of action and disease modifying characteristics. The unmet need in the vitiligo therapeutics market is considered to be significant and can be fulfilled by technologically advanced products with improved safety and efficacy profiles.
Weak Pipeline Lacking in Effective Therapeutic Options in Late Phase of Clinical Development
GlobalData’s research indicates that the vitiligo therapeutics market pipeline is weak as the pipeline has few therapeutic treatment options. There are seven potential treatment options in the pipeline across various phases of clinical development. Out of the seven pipeline candidates, three are melanocytes transplantation therapies and the remaining four are therapeutic treatments. None of the therapeutic treatment options in the pipeline is in the late stage of development. In Phase III there are three melanocytes transplantation therapies, which will improve the disease management through surgical treatment options. In terms of therapeutic treatment options all of the molecules in the pipeline are first-in-class. The only first-in-class molecule in Phase II, Scenesse (afamelanotide) from Clinuvel Pharmaceuticals, acts by stimulating alpha-melanocytes. Of the three first-in-class molecules from the preclinical phase, DRM02 of Dermira, is a topical kinase inhibitor whereas two molecules from Switch Biotech, SWT05104 and SWT05105 are melanocytes formation stimulators. Scenesse is an analogue of alpha melanocytes stimulating hormone and mimics its action. Treatment of vitiligo patients with Scenesse is expected to facilitate repigmentation by enhancing the growth of melanocytes, assisting in their migration to depigmented areas of skin and activating pigment production within these regions.
